PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - NYSE:PBH - US74112D1019 - Common Stock
62.09 USD
+0.28 (+0.45%)
62.09 USD
0 (0%)
Overall PBH gets a fundamental rating of 6 out of 10. We evaluated PBH against 195 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
PBH had a positive operating cash flow in the past year.
PBH had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
The Return On Assets of PBH (6.21%) is better than 90.77% of its industry peers.
With an excellent Return On Equity value of 11.48%, PBH belongs to the best of the industry, outperforming 87.69% of the companies in the same industry.
PBH has a better Return On Invested Capital (7.95%) than 84.62% of its industry peers.
PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is significantly below the industry average of 15.30%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROIC | 7.95% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
With an excellent Profit Margin value of 19.02%, PBH belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
In the last couple of years the Profit Margin of PBH has grown nicely.
PBH has a better Operating Margin (31.15%) than 94.87% of its industry peers.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
PBH has a better Gross Margin (56.13%) than 64.62% of its industry peers.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
PBH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for PBH has been reduced compared to 1 year ago.
Compared to 5 years ago, PBH has less shares outstanding
PBH has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.60 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
PBH has a Altman-Z score of 2.60. This is in the better half of the industry: PBH outperforms 69.23% of its industry peers.
The Debt to FCF ratio of PBH is 3.79, which is a good value as it means it would take PBH, 3.79 years of fcf income to pay off all of its debts.
PBH has a Debt to FCF ratio of 3.79. This is amongst the best in the industry. PBH outperforms 88.21% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
PBH has a Debt to Equity ratio of 0.55. This is in the lower half of the industry: PBH underperforms 62.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Altman-Z | 2.6 |
ROIC/WACC0.98
WACC8.1%
2.3 Liquidity
A Current Ratio of 4.38 indicates that PBH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.38, PBH is in the better half of the industry, outperforming 65.64% of the companies in the same industry.
A Quick Ratio of 2.99 indicates that PBH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.99, PBH is in line with its industry, outperforming 58.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.21%, which is quite good.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
The Revenue has been growing slightly by 0.63% in the past year.
The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
Revenue 1Y (TTM)0.63%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
3.2 Future
The Earnings Per Share is expected to grow by 3.32% on average over the next years.
PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.15% yearly.
EPS Next Y0.93%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue Next Year-2.19%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.56, the valuation of PBH can be described as correct.
Based on the Price/Earnings ratio, PBH is valued cheaper than 88.21% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.29, PBH is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 12.86, the valuation of PBH can be described as correct.
PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 83.59% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PBH to the average of the S&P500 Index (22.85), we can say PBH is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.56 | ||
| Fwd PE | 12.86 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaply inside the industry as 88.72% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 89.74% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.41 | ||
| EV/EBITDA | 10.35 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)14.63
PEG (5Y)1.53
EPS Next 2Y3.24%
EPS Next 3Y2.71%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
62.09
+0.28 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.07%
Inst Owner Change0.06%
Ins Owners1.29%
Ins Owner Change5.74%
Market Cap3.06B
Analysts84.44
Price Target85.27 (37.33%)
Short Float %3.18%
Short Ratio2.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.66%
Min EPS beat(2)-5.96%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)-0.37%
Min EPS beat(4)-5.96%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)-47.18%
EPS beat(16)11
Avg EPS beat(16)-34.2%
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)1.46%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)1.46%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.45%
PT rev (1m)0%
PT rev (3m)-7.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.97%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.1%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-11.62%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)-3.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.56 | ||
| Fwd PE | 12.86 | ||
| P/S | 2.73 | ||
| P/FCF | 11.41 | ||
| P/OCF | 11.08 | ||
| P/B | 1.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.35 |
EPS(TTM)4.58
EY7.38%
EPS(NY)4.83
Fwd EY7.78%
FCF(TTM)5.44
FCFY8.77%
OCF(TTM)5.6
OCFY9.02%
SpS22.76
BVpS37.71
TBVpS-19.66
PEG (NY)14.63
PEG (5Y)1.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROCE | 10.5% | ||
| ROIC | 7.95% | ||
| ROICexc | 8.3% | ||
| ROICexgc | 73.5% | ||
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% | ||
| FCFM | 23.91% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexcg growth 3Y-14.1%
ROICexcg growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 26.62% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 72.82% | ||
| Profit Quality | 125.75% | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | 2.6 |
F-Score8
WACC8.1%
ROIC/WACC0.98
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
EPS Next Y0.93%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue 1Y (TTM)0.63%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
Revenue Next Year-2.19%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
EBIT growth 1Y5.97%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year7.03%
EBIT Next 3Y3.43%
EBIT Next 5Y2.94%
FCF growth 1Y26.73%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y25.6%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%